{"id":"ivonescimab-docetaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivonescimab simultaneously engages PD-L1 and CTLA-4 on immune cells, removing dual inhibitory signals and amplifying T-cell activation and proliferation. Docetaxel stabilizes microtubules to disrupt cell division, causing direct tumor cell death. The combination leverages both checkpoint immunotherapy and chemotherapy to target cancer through complementary mechanisms.","oneSentence":"Ivonescimab is a PD-L1/CTLA-4 bispecific antibody that blocks two immune checkpoints simultaneously, while docetaxel is a microtubule-stabilizing chemotherapy agent, together enhancing anti-tumor immunity and direct cytotoxic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:36.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (Phase 3)"},{"name":"Other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT07017673","phase":"PHASE2","title":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2025-07-25","conditions":"TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma","enrollment":34},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT07076693","phase":"PHASE2, PHASE3","title":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-06-03","conditions":"OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer","enrollment":97},{"nctId":"NCT06928389","phase":"PHASE3","title":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-06","conditions":"Non-Small Cell Lung Cancer","enrollment":536},{"nctId":"NCT06868732","phase":"PHASE1","title":"Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-03-12","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AK112, docetaxel"],"phase":"phase_3","status":"active","brandName":"Ivonescimab, docetaxel","genericName":"Ivonescimab, docetaxel","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivonescimab is a PD-L1/CTLA-4 bispecific antibody that blocks two immune checkpoints simultaneously, while docetaxel is a microtubule-stabilizing chemotherapy agent, together enhancing anti-tumor immunity and direct cytotoxic effects. Used for Non-small cell lung cancer (Phase 3), Other solid tumors (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}